TY - JOUR T1 - Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study JF - Lupus Science & Medicine JO - Lupus Sci Med DO - 10.1136/lupus-2022-000779 VL - 9 IS - 1 SP - e000779 AU - Miao Shao AU - Miao Miao AU - Xia Zhang AU - Xiaoying Zhang AU - Yuan An AU - Huifang Guo AU - Lingyan Lei AU - Qing Zhao AU - Yanjie Ding AU - Jin Lin AU - Rui Wu AU - Feng Yu AU - Yucui Li AU - Huali Miao AU - Liyun Zhang AU - Yan Du AU - Ruiying Jiao AU - Lixia Pang AU - Li Long AU - Xueming Yao AU - Xiaofei Shi AU - Fei Wang AU - Luping Cui AU - Lei Zhang AU - Shengyun Liu AU - Fuai Lu AU - Kangkai Luo AU - Simeng Zhao AU - Yongfu Wang AU - Xiao Wu AU - Qingwen Wang AU - Hongjiang Liu AU - Shulin Song AU - Xiaoyuan Zhou AU - Xiaoping Zhang AU - Shumei Shi AU - Hong Zhu AU - Yao Chen AU - Honglian Yu AU - Jie Wu AU - Ruiyun Yu AU - Wenqiang Fan AU - Shuang Liu AU - Jian Xu AU - Zhibin Chen AU - Lianjie Shi AU - Jing He AU - Xuewu Zhang AU - Zhanguo Li AU - Ru Li Y1 - 2022/11/01 UR - http://lupus.bmj.com/content/9/1/e000779.abstract N2 - Objective Infection is a major cause of death in patients with SLE. This study aimed to explore the infection rate in patients with SLE receiving a low dose of intravenous cyclophosphamide (IV-CYC).Methods Clinical parameters of 1022 patients with SLE from 24 hospitals in China were collected. Patients were divided into the short-interval and lower-dose (SILD, 400 mg every 2 weeks) IV-CYC group and the high-dose (HD, 500 mg/m2 of body surface area every month) IV-CYC group. The clinical data and infection rate between the two groups were compared.Results Compared with HD IV-CYC, the infection rate of the SILD IV-CYC group was significantly lower (13.04% vs 22.27%, p=0.001). Respiratory tract infection (10.28% vs 15.23%, p=0.046) and skin/soft tissue infection (1.78% vs 4.3%, p=0.040) were significantly decreased in the SILD IV-CYC group. Moreover, infections occurred most likely in patients with SLE with leucopenia (OR 2.266, 95% CI 1.322 to 3.887, p=0.003), pulmonary arterial hypertension (OR 2.756, 95% CI 1.249 to 6.080, p=0.012) and >15 mg/day of glucocorticoid (OR 2.220, 95% CI 1.097 to 4.489, p=0.027).Conclusions SILD IV-CYC showed a lower frequency of infection events than high-dose IV-CYC in patients with SLE.The data used during the current study are available from the corresponding author on reasonable request. ER -